hVIVO PLC (AIM:HVO) reaffirmed revenue guidance for the year and said profit margins would be at the upper end of the range as it delivered a record first half.
It expects revenue to be £62 million for the 12 months and says £100 million is achievable by 2028.
Turnover for the six months ended June 30 was up 31% at £35.6 million, while the contract research group's operational gearing was apparent as underlying earnings (EBITDA) grew 68% to £8.7 million.
Its cash balance grew by £5.8 million to £37.1 million, while hVIVO, a specialist in testing products for infectious and respiratory diseases, reported an order book of £71 million.
"After an exceptionally strong first half with record revenues and margins, hVIVO enters the remainder of the year with FY24 revenue guidance fully contracted and good visibility into 2025," said CEO Yamin 'Mo' Khan.
Looking ahead, hVIVO told investors that the pipeline of live opportunities continues to expand, including interest in new challenge models and new revenue streams with short- to medium-term potential opportunities of £40 million.
Among the highlights of the period just gone was the opening of a new, expanded facility at Canary Wharf in East London.
As a result, "operational efficiencies are set to continue to improve with the expansion of our services, improved automation", said CEO Khan.